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and 555MBq (15mCi) fixed dose regimens respectively. The data on demographic
(age, gender), clinical (presence of eye disease, the size/type of goiter) and biochem-
ical variables (serum Thyroid Stimulating Hormone -TSH) were obtained. Primary
outcome is to cure hyperthyroidism by rendering the patient either euthyroid or
hypothyroid within 6months of single dose RAI therapy. Statistical analysis was
carried out with SPSS version 15.0 and the level of statistical significance was taken
as P  0.05. RESULTS: Three (3) males (15%) and 17 females (85%) received RAI
therapy for Graves’ hyperthyroidism. Their mean age was 49.4 years (range of
25-75years). Fixed doses of 370MBq (10mCi) and 555MBq (15mCi) both produced a
response or cure rate of 100%. Overall, 65% and 35% were made hypothyroid
(TSH6.1mIU/L) and euthyroid (TSH0.21-6.0mIU/L) respectively. The incidence of
hypothyroidism was 66.6% with fixed dose of 370MBq (10mCi) and 62.5% with fixed
dose of 555MBq (15mCi) within 6months post RAI therapy. There was no significant
difference in the incidence of hypothyroidism produced by the two fixed doses of
RAI therapy. CONCLUSIONS: Radioactive iodine at fixed doses of 370MBq (10mCi)
and 555MBq (15mCi) was highly effective for the treatment of Graves’ hyperthy-
roidism, with a cure rate of 100%. Fixed doses of 370MBq (10mCi) and 555MBq
(15mCi) produced incidences of hypothyroidism of 66.6% and 62.5% respectively
within 6 months of RAI therapy which are not statistically different.
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OBJECTIVES: Metformin is an established first line treatment for type 2 diabetes
mellitus (T2DM) patients but intensification of oral antidiabetic therapy is usually
required over time. The Effectiveness of Diabetes control with vildaGliptin and
vildagliptin/mEtformin (EDGE) study compared effectiveness and safety of vilda-
gliptin and other oral antidiabetic drugs in 45868 worldwide patients with T2DM
inadequately controlled by monotherapy under real life conditions. Here we dem-
onstrate effectiveness results for patients receiving vildagliptin or sulfonylurea
(SU) add-on to metformin in Germany. METHODS: T2DM patients inadequately
controlled with current monotherapy are eligible after add-on treatment was cho-
sen by the physician based on patient’s need. Effectiveness was assessed by HbA1c
drop and by means of a composite endpoint assessing the proportion of patients
responding to treatment (HbA1c  7.0) without proven hypoglycemic event and
without significant weight gain (5%) after 12 months of treatment. RESULTS: In
total 8887 patients were enrolled in Germany; 5779 patients received metformin
vildagliptin (4960) or metforminSU (819). Mean age was 62.611.1 years, mean
T2DM duration was 5.84.9 years. Average BMI was 30.85.5 kg/m2. Mean baseline
HbA1c was comparable (vildagliptin:7.8%; SU:7.7%). After 12 months of treatment,
HbA1c decreased in both cohorts (vildagliptin:-0.69%; SU:-0.46%) but the drop was
significantly greater with vildagliptin compared to SU (	-0.23%; CI95% -0.32 -0.14;
p0.001). In the vildagliptin cohort, a higher proportion of patients reached the
composite endpoint (HbA1c7, no hypoglycemic events, no weight gain) when
compared to the SU cohort (vildagliptin:25.5%; SU:17.7%; p 0.001). The overall
recorded number of hypoglycemic events was low (vildagliptin:0.11%; SU:0.41%)
but almost 4-fold higher in the SU cohort when compared to the vildagliptin cohort.
CONCLUSIONS: In real life clinical practice in Germany, vildagliptin is associated
with a greater HbA1c-drop, less hypoglycemic events and a higher proportion of
patients reaching target HbA1c without hypoglycemia and weight gain compared
to SU.
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OBJECTIVES:No studies are available evaluating the impact of rapid-acting insulin
analogues on long-term outcomes. Our aim was to compare the use of rapid-acting
insulin analogues versus human regular insulin in relation to the occurrence of
diabetic complications in a cohort of diabetic patients. METHODS: Diabetic pa-
tients free of macrovascular disease at baseline were followed up for 3 years. All
patients were residents in Abruzzo Region of central Italy. The incidence of diabetic
complications was ascertained by hospital discharge claims. Patients receiving
human regular insulin were compared with those treated with rapid-acting insulin
analogues. HRs and 95% CIs of any diabetic complication and macrovascular, mi-
crovascular and metabolic complications were estimated separately using Cox pro-
portional hazard models adjusted for patients’ characteristics. Propensity score
matching was also used to adjust for significant difference in the baseline charac-
teristics between the two treatment groups. RESULTS: Overall, 2,286 patients were
included into the analyses: 914 in the human regular insulin group and 1,372 in the
rapid-acting insulin analogue group. During the 3-year follow-up, there were 286
incident events (31.3%) in the human regular insulin group and 235 (17.1%) in the
rapid-acting insulin analogue group, with a difference between the two treatment
groups in the cumulative HR for any diabetic complications that increased over
time (p0.0001). After adjustment for covariates, rapid-acting insulin analogues
had a HR (95% CI) of 0.63 (0.51-0.77) for any diabetes-related complication and HRs
of 0.62 (0.48-0.79) and 0.44 (0.27-0.73) for macrovascular and metabolic complica-
tions respectively, as compared with human regular insulin users. No difference
between the two groups was found for microvascular complications. All endpoint
results were supported by propensity score-based matched-pair analyses.
CONCLUSIONS:Our findings suggest that the use of rapid-acting insulin analogues
is associated with a lower risk of cardiovascular and metabolic complications com-
pared with human regular insulin use.
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OBJECTIVES: To assess the impact of hypoglycaemic events on BMI evolution and
HbA1c control in diabetes mellitus treated patients. METHODS: A retrospective
study was undertaken, based on the new French IMS Lifelink Diabetes Cohort,
investigating evolution of HbA1c, evolution of BMI and number of hypoglycaemia
events. Patient characteristics, glycemic control, therapeutic strategies, risk factors
and diabetes complications are introduced as descriptive variables. RESULTS: At
the end of May, more than 3 000 diabetic French patients (median and mean age
66.0, 56% men, 11.5% DT1 and 88.5% DT2) have been included in this cohort (4 000
patients expected in September and 5 000 at the end of the year). Average DT2
oldness is 10 years; 48% of the DT2 patients are treated with monotherapy, 36.0%
with a bi-therapy and 13.5% are receiving three and more drugs; median DT2 HbA1c
is 6.9%. Half of the DT2 patients are obese. 143 patients have today 5 months of
follow up in the database; on this period, 7% of the patients had at least one
hypoglycaemic event while evolution HbA1c and BMI rate are respectively -0.4%
(-0.06 points) and -0.14% (-0.07 points). Diabetes control of patients who had hypo-
glycaemic events has declined (0.07 points of HbA1c) while BMI has increased
(0.02 points); outcomes are opposite (with no statistical differences due to too low
sample) for diabetic patients without hypoglycaemic events (respectively, -0.07
points and -0.08 points). CONCLUSIONS:We have identified on a small sample size
a signal showing a weight increase and a worsening of HbA1c control in diabetes
patients with hypoglycaemic events. The IMS Lifelink Diabetes Cohort sample in-
crease expected until October 2012, as well as the longer duration of patient follow
up will allow an updated and more robust analysis of the possible impact of hypo-
glycaemic events on weight and HbA1c control.
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OBJECTIVES: To assess the effectiveness, tolerability and treatment adherence of
vildagliptin in type 2 diabetes patients under real-life conditions of care in France,
following a request by the French Health Technology Agency. METHODS: A repre-
sentative sample of type 2 diabetes patients initiating a treatment with vildagliptin
was enrolled in a 2 years follow up observational cohort in 2010 by a national
sample of endocrinologists and general practitioners. Data collected included so-
cio-demographic characteristics, clinical history, treatment and laboratory data.
We report here an interim follow up analysis. RESULTS: A total of 482 GPs and 84
endocrinologists have included 1,702 patients and 1,463 are analyzed in these in-
terim results up to 18 months (1,246 at 12 months and 700 at 18 months). 60% were
males, mean age was 63 (9) years, and mean disease duration was 7 (6.5) years.
The mean HbA1c level decreased rapidly from 7.8% (sd1.3) before vildagliptin
prescription to 7.1% (sd1.0) at 6 months and remained stable thereafter, respec-
tively 7.0% (sd1.1), and 6.9% (sd0.9) at 12 and 18 months after vildagliptin initi-
ation. The percentages of patients with alanine or aspartate aminotransferase
above 120 UI were 0.5% before vildagliptin prescription and respectively 0.3%, 0.5%
and 0.2% at 6, 12, and 18 months after vildagliptin prescription. The mean glomer-
ular filtration rate as calculated with the MDRD formula was 94.7 ml/minute before
vildagliptin prescription and 95.1, 95.3, and 95.1, respectively at 6, 12, and 18
months after vildagliptin prescription. The incidence of severe hypoglycemia (re-
quiring third party assistance) has been estimated at 0.24/ 100vildagliptin treated
patients years (CI95%[0.07,0.55]). The proportion of patients treated with vilda-
gliptin remained high over the course of the study: 96.6% (CI95%[95.6,97.5]) after 6
months and 91.6% (CI95%[90.1%,93.1%]) after one year.CONCLUSIONS:Vildaglip-
tin showed sustained effectiveness in terms of reduction in HbA1c over 18 months,
with a low incidence of hypoglycemia.
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OBJECTIVES: In spite of high prevalence of diabetes, there is a paucity of data on
epidemiology, clinical outcome measures, medication treatment pattern and
health care resource utilization among the Aboriginal people in Ontario. The ob-
jectives of this study were to follow a cohort of newly diagnosed Aboriginal people
with diabetes in South-Western Ontario (SWO) over a 5-year time horizon to doc-
ument their baseline characteristics, clinical outcomes and resource utilization.
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